Limb Girdle Muscular Dystrophy Treatment Market is expected to reach US$ 1.96 billion by 2032 | Top Companies - Genethon, Atamyo Therapeutics, Vita Therapeutics, Inc.

Market Size and Growth:

The Global Limb Girdle Muscular Dystrophy Treatment Market reached US$ 1.36 billion in 2024 and is expected to reach US$ 1.96 billion by 2032, growing with a CAGR of 4.7% during the forecast period 2025-2032. The Market is growing due to increasing awareness, advancements in gene therapies, and rising prevalence of limb girdle muscular dystrophy worldwide.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/limb-girdle-muscular-dystrophy-treatment-market?sz

The Limb Girdle Muscular Dystrophy (LGMD) Treatment Market encompasses therapies, drugs, and interventions aimed at managing LGMD, a group of genetic disorders causing progressive weakness and wasting of the hip and shoulder muscles. The market includes gene therapies, pharmacological treatments, physical therapy solutions, and supportive care aimed at improving patient mobility, quality of life, and slowing disease progression globally.

Industry Recent Developments: United States

✅ November 2025: Sarepta is actively seeking FDA approval for what could be the first gene therapy for limb girdle muscular dystrophy.​

✅ October 2025: BridgeBio Pharma announced positive topline results from its Phase 3 FORTIFY study evaluating BBP-418 for LGMD type 2I/R9, showing sustained functional improvements and biomarker reductions.​

✅ September 2025: Patients treated with AskBio's AB-1003 gene therapy for LGMD showed mild-to-moderate treatment-emergent adverse effects, supporting ongoing clinical development.

Industry Recent Developments: Japan

✅ November 2025: Growing demand for AI-powered remote diagnostics and telemedicine tools is creating new opportunities for LGMD management solutions in Japan.​

✅ October 2025: Atamyo Therapeutics initiated a study to evaluate ATA-200 safety in pediatric LGMD type 2c/R5 patients via intravenous infusion.​

✅ September 2025: Japan continues steady LGMD market expansion supported by strong genetic research investments and clinical studies at national neurology institutions.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/limb-girdle-muscular-dystrophy-treatment-market?sz

FDA / Regulatory Approvals & Milestones in 2025:

✅ Sarepta Therapeutics (SRPT) - for its gene‐therapy program SRP‐9005 (for LGMD 2C/R5): U.S. FDA cleared screening and dosing to proceed in the first‐in‐human Study SRP‐9005‐101 (COMPASS) in 2025.

✅ Sarepta - for its gene‐therapy program SRP‐9003 (for LGMD 2E/R4): After completion of enrollment/dosing, a pre‐BLA meeting with FDA indicated eligibility for the accelerated approval pathway; the company plans a Biologics License Application submission in the second half of 2025.

✅ Atamyo Therapeutics - for its gene‐therapy program ATA‐100 (for LGMD 2I/R9): Company announced completion of the dose‐finding study and receipt of U.S. Rare Pediatric Disease Designation in April 2025.

✅ AskBio - for its gene‐therapy program AB‐1003 (for LGMD 2I/R9): First patient dosed in a Phase 1/2 trial in March 2025; the campaign also holds Orphan Drug and Rare Pediatric Disease designations from FDA.

✅ Sarepta - in June 2025 the FDA granted a Platform Technology Designation for the AAV vector (rAAVrh74) used in SRP‐9003 for LGMD2E/R4, which could expedite future gene‐therapy development in the LGMD space.

Mergers, Acquisitions & Collaborations

✅ Sarepta entered a partnership with Myonexus Therapeutics (a spin‐out from Nationwide Children's Hospital) focused on gene therapy programs for distinct LGMD forms. Under the agreement, Sarepta made an upfront payment (~US$60 million) and secured a fixed‐price option to acquire Myonexus with milestone and contingent payments.

✅ Sarepta also closed a global licensing and collaboration agreement with Arrowhead Pharmaceuticals in early 2025, which added rights to clinical‐ and pre‐clinical‐stage programs in muscle/neuromuscular/rare diseases thereby broadening its muscle‐disease pipeline beyond LGMD.

Major Key Players:

Jubilant Cadista Pharmaceuticals Inc.
Sarepta Therapeutics, Inc.
ML Bio Solutions
Genethon
Asklepios BioPharmaceutical, Inc.
Atamyo Therapeutics
Vita Therapeutics, Inc.
Edgewise Therapeutics
BridgeBio Inc.
Hansa Biopharma

Market Growth Drivers:

Advancements in gene therapy, molecular diagnostics, and personalized medicine enhancing early diagnosis and targeted therapies.

Growing research and development initiatives and a robust pipeline of novel treatments including gene therapies, enzyme replacement therapies, and RNA-based therapies.

Increasing awareness among patients and caregivers, supportive regulatory incentives for orphan drugs, and government initiatives promoting healthcare infrastructure and rare disease research.

Segments Covered in the Limb Girdle Muscular Dystrophy Treatment Market:

By Type: Limb-girdle Muscular Dystrophy Type 1, Limb-girdle Muscular Dystrophy Type 2.

By Treatment: Medications, Gene Therapy, Others.

By End User: Hospitals, Ambulatory Surgical Centers, Others.

Regional Analysis for Limb Girdle Muscular Dystrophy Treatment Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=limb-girdle-muscular-dystrophy-treatment-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Limb Girdle Muscular Dystrophy Treatment market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Limb Girdle Muscular Dystrophy Treatment Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Limb Girdle Muscular Dystrophy Treatment market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Limb Girdle Muscular Dystrophy Treatment Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Limb Girdle Muscular Dystrophy Treatment market?

➠ Who are the global key manufacturers of the Limb Girdle Muscular Dystrophy Treatment Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Limb Girdle Muscular Dystrophy Treatment market opportunities and threats faced by the vendors in the global Limb Girdle Muscular Dystrophy Treatment Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Limb Girdle Muscular Dystrophy Treatment market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.